JPMorgan raised the firm’s price target on Myriad Genetics to $17 from $14 and keeps an Underweight rating on the shares post the Q4 report. The analyst looks for sustainability of Myriad’s recent growth translating into profitability, particularly as the company launches several new products into highly competitive markets.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
- Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
- MYGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health